Computational chemistry company Evogene Ltd (NASDAQ:EVGN) (TASE:EVGN) on Tuesday announced an expanded phase of its partnership with Google Cloud.

In this new phase, the collaboration will focus on developing and integrating advanced AI agents into Evogene's ChemPass AI platform, its proprietary engine for small-molecule discovery and optimisation, using Google Cloud's Vertex AI platform. The goal is to increase the speed, precision, and efficiency of identifying and optimising small molecules for drug and ag-chemical development.

The initial phase of the partnership focused on building a generative AI foundation model that now serves as a core component of ChemPass AI.

When integrated into ChemPass AI, AI agents are designed to automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyse cycles, and improve the accuracy and success rate of designing small-molecule based products.